Hamai, Y.; Ibuki, Y.; Kurokawa, T.; Hirohata, R.; Ohsawa, M.; Kitasaki, N.; Emi, M.; Okada, M.
Relationship of Immune-Related Adverse Events with Tumor Response and Prognosis in Esophageal Squamous Cell Carcinoma Following Nivolumab Monotherapy. Cancers 2024, 16, 3529.
https://doi.org/10.3390/cancers16203529
AMA Style
Hamai Y, Ibuki Y, Kurokawa T, Hirohata R, Ohsawa M, Kitasaki N, Emi M, Okada M.
Relationship of Immune-Related Adverse Events with Tumor Response and Prognosis in Esophageal Squamous Cell Carcinoma Following Nivolumab Monotherapy. Cancers. 2024; 16(20):3529.
https://doi.org/10.3390/cancers16203529
Chicago/Turabian Style
Hamai, Yoichi, Yuta Ibuki, Tomoaki Kurokawa, Ryosuke Hirohata, Manato Ohsawa, Nao Kitasaki, Manabu Emi, and Morihito Okada.
2024. "Relationship of Immune-Related Adverse Events with Tumor Response and Prognosis in Esophageal Squamous Cell Carcinoma Following Nivolumab Monotherapy" Cancers 16, no. 20: 3529.
https://doi.org/10.3390/cancers16203529
APA Style
Hamai, Y., Ibuki, Y., Kurokawa, T., Hirohata, R., Ohsawa, M., Kitasaki, N., Emi, M., & Okada, M.
(2024). Relationship of Immune-Related Adverse Events with Tumor Response and Prognosis in Esophageal Squamous Cell Carcinoma Following Nivolumab Monotherapy. Cancers, 16(20), 3529.
https://doi.org/10.3390/cancers16203529